Ergomed logo

ERGO - Ergomed News Story

815p 0.0  0.0%

Last Trade - 19/10/20

Sector
Healthcare
Size
Mid Cap
Market Cap £396.9m
Enterprise Value £388.8m
Revenue £73.5m
Position in Universe 582nd / 1799

Ergomed plc - Notice of Interim Results

Thu 20th August, 2020 7:00am
RNS Number : 6329W
Ergomed plc
20 August 2020
 

 

PRESS RELEASE

 

Notice of Interim Results

 

 

Guildford, UK - 20 August 2020: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialized services to the pharmaceutical industry, will announce its interim results for the six months ending 30 June 2020 on 22 September 2020.

 

Miroslav Reljanović, Executive Chairman and Richard Barfield, Chief Financial Officer will host a virtual presentation and conference call for analysts at 9am BST on the day of the results.

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Sue Stuart

ergomed@consilium-comms.com

Matthew Neal / Olivia Manser




MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognized specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBLGDIRUBDGGC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.